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Summary  We  present  the  case  of  a  58-year-old  male  with  coronary  artery  disease  and  a
signiﬁcant  stenosis  of  the  left  circumﬂex  artery  that  was  preceded  by  a  coronary  aneurysm.
The  stenosis  and  aneurysm  were  treated  successfully  with  a  coronary  stent  graft.  The  patient
subsequently  developed  in-stent  restenosis  (ISR).  The  ISR  was  then  successfully  treated  with  a
paclitaxel-eluting  stent  (PES).  The  patient  has  been  followed  clinically  for  4—6  years  without
recurrence  of  his  anginal  symptoms.  This  is  the  ﬁrst  description  in  the  literature  of  which  we  are
aware  of  the  successful  treatment  of  an  ISR  of  a  coronary  stent  graft  with  a  PES  with  persistent
long-term  clinical  effectiveness.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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The  patient  is  a  58-year-old  male  with  a  long  history  of
coronary artery  disease.  He  had  undergone  multiple  percu-
taneous coronary  interventions  in  both  the  right  coronary
artery (RCA)  and  proximal  left  anterior  descending  artery
(LAD) with  bare  metal  stents.  In  December  2003  during  fol-
low  up  for  angina-type  chest  discomfort,  a  perfusion  study
demonstrated inferior  wall  reversibility.  The  patient  under-
went cardiac  catheterization  which  demonstrated  total
occlusion of  the  proximal  RCA  which  was  previously  stented
from the  ostium  to  the  distal  vessel  and  now  ﬁlled  from
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doi:10.1016/j.jccase.2011.03.008eft-to-right  and  right-to-right  collaterals.  The  left-to-right
ollaterals are  well  developed  from  the  LAD  and  the  left  cir-
umﬂex artery  (LCA)  all  the  way  up  to  the  RCA  distal  stents.
owever, there  were  also  extensive  bridging  collaterals  with
ery small  caliber  side-branches  at  the  occlusion  cap.  Even-
ually, the  bridging  collaterals  form  a  very  thin  column  of
aint contrast  ﬁlling  all  the  way  down  to  the  distal  stents.  A
ew 1  cm  aneurysmal  segment  in  the  midportion  of  the  LCA
ith a  50%  stenosis  just  before  the  aneurysmal  segment  fol-
owed  by  an  80%  stenotic  hazy  lesion  at  the  distal  portion  of
he aneurysm  ‘‘wrap-around-aneurysmal-candy’’  (Fig.  1A),
ollowed  by  a  trifurcating  obtuse  marginal  branch  (Fig.  1A).
The  patient  was  seen  in  the  clinic  two  weeks  after
is diagnostic  angiogram.  Options  included  percutaneous
ntervention to  re-canalize  the  RCA  or  treatment  of  the
neurysm with  both  the  proximal  and  distal  portion  lesions
ith a  covered  stent.  Alternatively,  bypass  surgery  was  an
Published by Elsevier Ltd. All rights reserved.
e14  K.B.  Thani  et  al.
Figure  1  (A)  Aneurysmal  dilatation  [arrow]  of  the  left  circumﬂex  coronary  artery  which  is  immediately  followed  by  a  tight  stenosis
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Harrow  head].  (B)  The  immediate  angiographic  results  following
n-stent  restenosis  of  the  JOSTENT®GraftMaster  coronary  stent  
ption,  but  his  LAD  was  patent  and  his  left  ventricular
unction was  normal.  The  RCA  total  occlusion  was  unfavor-
ble to  percutaneous  approach  in  view  of  the  presence  of
ide branches  at  the  occlusion  cap  and  bridging  collaterals.
urthermore, the  posterior  descending  artery  and  the  pos-
erolateral branch  were  ﬁlled  by  well-developed  collaterals
rom the  left  coronary  system  up  to  the  distal  RCA  segment.
he patient  preferred  the  percutaneous  approach.  There-
ore, we  elected  to  treat  the  left  circumﬂex  lesion  and  not  to
ntervene on  the  RCA.  The  covered  stent  approach  was  pro-
osed in  view  of  the  lesion  complexity  and  morphology.  The
rovisional stenting  approach  probably  would  require  either
wo short  stents  leaving  a  sticking  stent  in  the  aneurysmal
egment or  a  long  stent  with  an  exposed  and  unopposed
tent struts  in  the  mid  portion  of  the  aneurysm  and  would
e at  risk  for  stent  thrombosis.
The  patient  proceeded  to  intervention  in  March  2004.
he mid  LCA  lesion  distal  to  the  aneurysm  was  predi-
ated with  a  2.75  ×  18  mm  Power  Sail  balloon  (Guidant
orporation, Santa  Clara,  CA,  USA)  to  10  atmospheres.
 3.0  ×  19  mm  JOSTENT®GraftMaster  coronary  stent
raft (Abbott,  Redwood  City,  CA,  USA)  was  then  delivered
o the  lesion  covering  the  aneurysmal  segment,  which  was
eployed at  16  atmospheres.  Final  angiography  revealed  no
issection or  dye  staining  with  resolution  of  the  aneurysmal
egment (Fig.  1B).
Nine  months  subsequent  to  the  covered  stent  implan-
ation he  began  to  have  anginal  symptoms  on  exercise.
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cTENT®GraftMaster  coronary  stent  graft  placement.  (C)  Severe
.  (D)  The  result  following  paclitaxel-eluting  stent.
e  underwent  repeated  coronary  angiography  reveal-
ng a  99%  area  of  in-stent  restenosis  (ISR)  in  the  LCA
OSTENT®GraftMaster  coronary  stent  graft  (Fig.  1C).  There-
ore, the  lesion  was  predilated  with  a  2.5  ×  9  mm  Maverick
alloon (Boston  Scientiﬁc,  Natick,  MA,  USA)  at  20  atmo-
pheres. A  3.0  ×  20  mm  Taxus  stent  (Boston  Scientiﬁc,
atick, MA,  USA)  was  then  deployed  to  14  atmospheres  cov-
ring the  previously  placed  JOSTENT®GraftMaster  coronary
tent graft  (Fig.  1D).
Since  his  last  stenting  procedure,  the  patient  has
emained asymptomatic  and  active.  He  continues  to  undergo
outine annual  stress  testing.  His  last  study  was  completed
n November  2008  demonstrating  no  wall  motion  abnormal-
ties on  stress  echocardiography.  Therefore,  no  follow-up
ngiography was  performed.
iscussion
e  present  a  patient  who  has  an  extensive  history  of  sig-
iﬁcant coronary  artery  disease  who  developed  a  coronary
neurysm followed  by  a  tight  stenosis  and  was  successfully
reated with  a  JOSTENT®GraftMaster  coronary  stent  graft.
e subsequently  developed  ISR  within  the  covered  stent  and
as treated  with  placement  of  a  paclitaxel-eluting  stent
PES). The  patient  has  remained  symptom-free  for  the  inter-
ening  4—6  years  while  able  to  maintain  a  high  exercise
apacity.
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Coronary  artery  aneurysms  are  deﬁned  as  localized
dilatation of  a  coronary  artery  greater  than  1.5  times
the normal  adjacent  reference  vessel.  They  may  occur  in
response to  occlusive  coronary  artery  disease  in  up  to  50%
of cases.  In  addition,  balloon  angioplasty,  atherectomy,  and
excimer laser  angioplasty  have  been  implicated  in  their  for-
mation at  the  sites  of  previous  intervention.  Sluggish  or
turbulent coronary  blood  ﬂow  with  resultant  ischemic  symp-
toms can  occur  regardless  of  the  severity  of  the  associated
stenotic lesion.  Potential  complications  that  could  happen
include rupture,  tamponade,  arterial  occlusion,  and  sudden
cardiac death  [1].
There  have  been  multiple  reports  in  the  literature  show-
ing successful  treatment  of  coronary  artery  aneurysms  with
covered stents  [2—4].  The  use  of  covered  stents  to  treat
coronary aneurysms  is  off  label  and  its  use  in  our  patient
was pursued  only  after  detailed  discussion  with  the  patient.
While the  treatment  of  the  aneurysm  was  successful,  our
patient developed  signiﬁcant  ISR  within  the  covered  stent.
This is  the  ﬁrst  description  in  the  literature  of  which  we
are aware  of  the  successful  treatment  of  an  ISR  of  a coro-
nary stent  graft  with  a  PES  with  persistent  long-term  clinical
effectiveness.
The JOSTENT®GraftMaster  coronary  stent  graft  is  com-
posed of  a  polytetraﬂuoroethylene  membrane  sandwiched
between two  bare  metal  stents.  Previous  studies  evalu-
ating covered  stent  restenosis  (>50%  diameter  stenosis)
have shown  rates  similar  to  bare  metal  stents  with  30%
restenosis at  6-month  follow  up  [5].  The  pattern  of  ISR
most commonly  seen  in  covered  stents  has  been  at  the
stent margins  [6].  A  recent  study  utilizing  optical  coher-
ence tomography  and  angioscopy  reported  that  ISR  in  the
proximal edge  of  the  stent  was  organized  white-thrombus
with non-endothelialized  areas  in  the  mid  stent.  The  authors
concluded that  neointimal  hyperplasia  which  is  the  most
common process  in  typical  stent  restenosis  has  a  limited  role
in covered  stent  restenosis  [7].
At  the  time  the  patient  presented,  we  elected  to  treat
the ISR  with  a  PES.  This  approach  is  supported  by  Taxus  V
ISR trial  which  demonstrated  the  superiority  of  PES  when
compared to  vascular  brachytherapy  in  bare  metal  stents  by
showing a  lower  incidence  of  ischemia-driven  target  vessel
revascularization at  24  months  of  follow  up  [8].  However,
recent studies  have  suggested  that  ‘‘limus-’’  eluting  stents,
particularly the  newer  generation  versions,  are  superior  to
PES and  may  be  better  alternatives  in  future  cases  [9,10].Conclusion
In  conclusion,  we  demonstrate  the  successful  treatment
of covered  stent  ISR.  Even  though  stent  grafts  are  notaft  with  a  paclitaxel-eluting  stent  e15
requently  used  and  are  mainly  utilized  in  coronary  perfora-
ions, they  do  have  a  high  restenosis  rate  once  implanted.
his case  suggests  that  drug-eluting  stents  can  be  used  if
SR develops,  which  adds  another  potential  treatment  to  the
ES armamentarium  as  a  revascularization  strategy  in  these
atients.
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